Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Ziran Zhang PhD"'
Autor:
Jie Zhang PhD, Di Wu PhD, Ziran Zhang PhD, Jieran Long PhD, Guangming Tian PhD, Yang Wang PhD, Xiangjuan Ma PhD, Xiaoling Chen PhD, Jindi Han PhD, Weiheng Hu PhD, Ling Dai PhD, Jun Nie PhD, Jian Fang PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in random
Externí odkaz:
https://doaj.org/article/31934071c47149bf87053edf3807d5a3
